Daraprim Drug Pricing Suit Against Shkreli And Vyera May Signal Future FTC Actions

In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.

NEW YORK - JUNE 29, 2017 - Martin Shkreli leaves federal court on June 29, 2017 in Brooklyn, New York.
FTC and New York Attorney General file antitrust suit againt former Turing Pharmaceuticals CEO Martin Shkreli

More from Legal & IP

More from Pink Sheet